ArticleContemporary clinical trials communications2026
Activating the vagus nerve-adrenal anti-inflammatory axis to delay aging: A randomized controlled trial protocol.
Article in Contemporary clinical trials communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aging is a primary risk factor for chronic diseases, yet safe and effective interventions remain limited. Traditional Chinese Medicine (TCM) highlights the role of acupuncture in health preservation, with ST36 (Zusanli) being a key acupoint for longevity. Preclinical studies suggest ST36 acupuncture modulates inflammation and oxidative stress, but robust clinical evidence is lacking. This trial aims to evaluate the efficacy of ST36 acupuncture in delaying aging and preventing age-related diseases through biomarkers and clinical outcomes. Methods: A single-center, randomized, single-blinded, controlled trial will enroll 120 healthy participants aged 45-70 years. Participants will be allocated to manual acupuncture, sham acupuncture, or blank control groups. The intervention involves 36 sessions over 12 weeks. Primary outcomes include aging biomarkers (DNA methylation, plasma cytokines) and 3D facial/thermal imaging for biological age estimation. Secondary outcomes assess quality of life (SF-36) and sleep quality (PSQI). Adverse events will be systematically documented. Discussion: This study will provide evidence on the anti-aging effects of ST36 acupuncture and its potential integration into preventive healthcare. Results may inform strategies to address global aging challenges and promote healthy longevity. Trial registration: Chinese Clinical Trial Registry ChiCTR2500101531. Registered on 27 April 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.